Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159443 | 0.93 | ESR1 (0.42) | ESR1ESR2AR | |
| SCHEMBL2978686 | 0.91 | ESR1 (0.52) | ESR1ESR2ARVDR | |
| SCHEMBL1525824 | 0.90 | ESR1 (0.58) | ESR1ESR2ARVDR | |
| SCHEMBL2950878 | 0.86 | ESR1 (0.49) | ESR1ESR2ARVDRHDAC6 | |
| SCHEMBL14253999 | 0.82 | GAA (0.44) | ESR1ESR2ARVDRFFAR4 | |
| SCHEMBL2950031 | 0.82 | VDR (0.64) | ARVDRHDAC6HDAC3 | |
| SCHEMBL1525164 | 0.81 | ESR1 (0.52) | ESR1ESR2ARVDR | |
| SCHEMBL13236499 | 0.81 | VDR (0.56) | ARVDRHDAC6HDAC3 | |
| SCHEMBL2943185 | 0.81 | VDR (0.56) | ARVDRHDAC6HDAC3 | |
| SCHEMBL5156307 | 0.80 | AR (0.50) | ESR1ESR2ARVDRSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772425-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-7566803-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090018058-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-05-04 | — | — | US | disclosed |
| EP-1587906-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1565422-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004063345-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004048309-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP24A1, CYP2R1 | ESR1 182/4885ESR2 168/4885AR 719/4885 |
| US-20090018058-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | ESR1 275/4885ESR2 137/4885AR 560/4885 |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | ESR1 391/4885ESR2 171/4885AR 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.